



**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of

Docket No: Q76319

Yasuhiro KOUCHI, et al.

Appln. No.: 10/627,757

Group Art Unit: 1634

Confirmation No.: 3310

Examiner: Sitton, J.

Filed: July 28, 2003

For: GENE ASSAY METHOD FOR PREDICTING GLAUCOMA ONSET RISK

**SUBMISSION OF EXECUTED DECLARATION UNDER 37 C.F.R. §1.132**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith is a copy of an executed Declaration Under 37 C.F.R. §1.132 signed  
by Yasuhiro Kouchi.

Respectfully submitted,

Drew Hissong  
Registration No. 44,765

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE

**23373**

CUSTOMER NUMBER

Date: May 15, 2006



**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of

Docket No: Q76319

Yasuhiro KOUCHI, et al.

Confirmation No.: 3310

Appln. No.: 10/627,757

Group Art Unit: 1634

Filed: July 28, 2003

Examiner: Sitton, J.

For: GENE ASSAY METHOD FOR PREDICTING GLAUCOMA ONSET RISK

**DECLARATION UNDER 37 C.F.R. § 1.132**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

I, Yasuhiro Kouchi, hereby declare and state:

THAT I am one of the inventors of the invention disclosed and claimed in the above-identified application;

THAT I am a citizen of Japan;

THAT I have received the degree of Masters in Engineering in 1994 from Kyoto University;

THAT I have been employed by Sysmex Corp. since 1994, where I hold a position as a manager, with responsibility for development of new diagnostic technologies;

The following information pertains to the number of subjects in the non-patient and patient groups tested in Example 2 at pages 18 and 19 of the specification in the above-identified application.

With regard to the mutation at position 619 in SEQ ID NO:1 (see the second column in Table 1 at page 19), there were 70 subjects in the patient group and 120 subjects in the non-patient group. Of the subjects in the patient group, 1 subject was shown to have the mutation. None of the subjects in the non-patient groups had the mutation.

With regard to the mutation at position 898 in SEQ ID NO:1 (see the third column in Table 1 at page 19), there were 128 subjects in the patient group and 80 subjects in the non-patient group. Of the subjects in the patient group, 1 subject was shown to have the mutation. None of the subjects in the non-patient groups had the mutation.

I declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: 28 Apr 2006

Yasuhiro Kouchi

Yasuhiro Kouchi



**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of

Docket No: Q76319

Yasuhiro KOUCHI, et al.

Appln. No.: 10/627,757

Group Art Unit: 1634

Confirmation No.: 3310

Examiner: Sitton, J.

Filed: July 28, 2003

For: GENE ASSAY METHOD FOR PREDICTING GLAUCOMA ONSET RISK

**STATEMENT OF SUBSTANCE OF INTERVIEW**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Please review and enter the following remarks summarizing the interview conducted on October 6, 2005:

**REMARKS**

An Examiner's Interview Summary Record (PTO-413) was attached with the Office Action dated January 13, 2006.

During the interview, the following was discussed:

1. Brief description of exhibits or demonstration: none
2. Identification of claims discussed: all
3. Identification of art discussed: none
4. Identification of principal proposed amendments: none
5. Brief Identification of principal arguments: Applicants requested permission to elect two primer pairs used to amplify exons 7 and 10, i.e., SEQ ID NOs:21, 22, 27 and 28.
6. Indication of other pertinent matters discussed: none
7. Results of Interview: Examiner agreed


It is respectfully submitted that the instant STATEMENT OF SUBSTANCE OF INTERVIEW complies with the requirements of 37 C.F.R. §§1.2 and 1.133 and MPEP §713.04.

STATEMENT OF SUBSTANCE OF INTERVIEW  
U.S. Appln. No. 10/627,757

Q76319

It is believed that no petition or fee is required. However, if the USPTO deems otherwise, Applicant hereby petitions for any extension of time which may be required to maintain the pendency of this case, and any required fee, except for the Issue Fee, for such extension is to be charged to Deposit Account No. 19-4880.

Respectfully submitted,



Drew Hissong  
Registration No. 44,765

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE

**23373**

CUSTOMER NUMBER

Date: May 15, 2006